Publication

Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

Parry, M.
; 
Grist, E.
; 
Brawley, C.
; 
Proudfoot, J. A.
; 
Mendes, L.
; 
Lall, S.
; 
Hoyle, Alex P
; 
Sachdeva, Ashwin
; 
Liu, Y.
; 
Amos, C.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Parry, M.
Grist, E.
Brawley, C.
Proudfoot, J. A.
Mendes, L.
Lall, S.
Hoyle, Alex P
Sachdeva, Ashwin
Liu, Y.
Amos, C.
Sydes, M. R.
Jones, R.
Parmar, M. K.
Feng, F.
Sweeney, C. J.
Clarke, Noel W
Davicioni, E.
James, N. D.
Brown, L.
Attard, G.
Affiliation
Oncology Department - Treatment Resistance, UCL Cancer Institute - Paul O’Gorman Building, London, UK
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Parry M, Grist E, Brawley C, Proudfoot JA, Mendes L, Lall S, et al. Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial. Annals of Oncology. 2022 Sep;33(7):S1161-S. PubMed PMID: WOS:000866211601615.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625973
Embedded videos